This company has been marked as potentially delisted and may not be actively trading. NASDAQ:GNRX VanEck Vectors Generic Drugs ETF (GNRX) Price, Holdings, & News Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About VanEck Vectors Generic Drugs ETF (NASDAQ:GNRX) Get GNRX alerts:Sign Up Key Stats Today's Range$22.42▼$22.4250-Day Range$22.42▼$22.4252-Week Range$20.17▼$26.19Volume4 shsAverage Volume1,310 shsMarket Capitalization$3.36 millionAssets Under Management$3.36 millionDividend Yield0.04%Net Expense Ratio0.57%Aggregate RatingN/A ETF Overview Read More VanEck Vectors Generic Drugs ETF ExpensesTypeGNRXHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.56%0.56%0.54%0.53%Other Expenses2.44%0.47%0.56%0.52%0.56%Total Expense2.94%0.75%0.76%0.73%0.73%Fee Waiver-2.37%-0.67%-0.66%-0.50%-0.63%Net Expense0.57%0.60%0.63%0.63%0.60% Receive GNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VanEck Vectors Generic Drugs ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNRX ETF News HeadlinesAmplify Weight Loss Drug & Treatment ETF (THNR)August 4, 2024 | finance.yahoo.comVanEck Vectors Preferred Securities Ex Financials ETF declares monthly distribution of $0.1422December 4, 2023 | msn.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should buy in this market, this token might just be it.September 23 at 2:00 AM | Crypto 101 Media (Ad)GDIG ETF Stock Price HistoryNovember 10, 2023 | investing.comVanEck Announces Changes to ETF Product LineApril 18, 2023 | finance.yahoo.comVanEck AEX UCITS ETF (TDT)March 3, 2023 | investing.comSee More Headlines GNRX ETF - Frequently Asked Questions What other stocks do shareholders of VanEck Vectors Generic Drugs ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that VanEck Vectors Generic Drugs ETF investors own include SLR Investment (SLRC), Saul Centers (BFS), Virtus LifeSci Biotech Products ETF (BBP), Bellevue Healthcare (BBH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ArrowMark Financial (BANX) and Yamana Gold (AUY). Fund Details IssuerVan Eck Fund NameVanEck Vectors Generic Drugs ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNRX Inception Date1/12/2016 Fund ManagerHao-Hung (Peter) Liao, Guo Hua (Jason) Jin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkIndxx Global Generics & New Pharma Index CategorySector FocusHealth Care Development LevelBlended Development RegionGlobal Number of Holdings0 Fund Statistics Assets Under Management$3.36 million Average Daily Volume$591.00 Discount/Premium-0.42% Administrator, Advisor and Custodian AdministratorVan Eck Associates Corporation AdvisorVan Eck Associates Corporation CustodianThe Bank of New York Mellon Corporation DistributorVan Eck Securities Corporation Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCantor Fitzgerald Miscellaneous Outstanding Shares150,000BetaN/A Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report GNRX Sector ExposureGNRX Industry Exposure This page (NASDAQ:GNRX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Vectors Generic Drugs ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Vectors Generic Drugs ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNRX Stock Alerts